The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active
www.nature.com/articles/s41...
Fantastic new paper from Flavio Maina, Celia Sequera, Margherita Grattarola and colleagues at the @crcm.bsky.social
#CancerResearch, #CRCM, #LiverCancer
nature.com
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active - Nature Communications
Targeting histone deacetylases (HDACs) alone has shown limited success in solid tumours. Here, authors report that the HDAC1/2 inhibitor romidepsin confers responsiveness to receptor tyrosine kinase inhibitors, with enhanced therapeutic effects in models of hepatocellular carcinoma, leading to tumour regression and an immune-stimulatory profile.